Hanmi Pharm exports technology worth 500 billion KRW for new acute myeloid leukemia drug

[Asia Economy Reporter Seo So-jeong] Hanmi Pharmaceutical announced on the 4th that it has licensed out the FLT3 gene mutation inhibitor 'HM43239' (code name), a new drug under development for acute myeloid leukemia, to Aptose Biosciences (hereinafter Aptose).

The contract is valued at $420 million (approximately 500 billion KRW), and Hanmi Pharmaceutical will receive a confirmed signing fee of $12.5 million from Aptose, divided into $5 million in cash and $7.5 million worth of Aptose shares.

Subsequently, Hanmi will receive up to $407.5 million in milestone payments for clinical development, approval, and commercialization stages across multiple indications, with royalties on sales paid separately.

Aptose has secured exclusive rights to develop and commercialize HM43239 worldwide.

HM43239 is a drug candidate that dually inhibits the FLT3 mutation causing acute myeloid leukemia and spleen tyrosine kinase (SYK).

This content was produced with the assistance of AI translation services.